Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 6Prostatic Neoplasms 6Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Melanoma 5Testicular Neoplasms 4Stomach Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Triple Negative Breast Neoplasms 3Colonic Neoplasms 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Teratoma 2Squamous Cell Carcinoma of Head and Neck 2Osteosarcoma 2Optic Nerve Glioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Nasopharyngeal Neoplasms 2Multiple Myeloma 2Kidney Neoplasms 2Hematologic Neoplasms 2Familial ependymoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Carboplatin 2zimberelimab 1sirtratumab vedotin 1sacituzumab govitecan 1olaparib 1avelumab 1Oxaliplatin 1Nivolumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Urothelial Cancer × Oxaliplatin × Genitourinary × Clear all
NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡